Building biotech ecosystems in Asia: an East-West Summit podcast

Takeaways from BioCentury’s East-West Biopharma Summit focus on Japan, India, China, plus the NewCo Model

While the culling of companies in the biotech bear market may have yet to subside, creative cross-border dealmaking on innovative assets is spreading across Asia’s Arc of Innovation. Sciwind Biosciences Co. Ltd.’s Jing Xu and A*Star’s Lisa Ooi join BioCentury to wrap up the 4th annual BioCentury-BayHelix East-West Biopharma Summit in Singapore by discussing deal-making trends, the rise of new technologies and the deepening of biotech ecosystems from India to Japan.

Xu is VP and head of global strategy for Sciwind and a veteran of global VC Lyfe Capital;
Ooi is the former COO of Hummingbird Bioscience Pte. Ltd. who is now assistant chief executive biomedical research council at Singapore’s A*Star (the Agency for Science, Technology and Research).